Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KLRS by emailGet an email when KLRS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KLRS, unsubscribe in one click. Privacy
📣 What KLRS Says Is Next
first half of 2027 · “Preliminary data from the Phase 1b/2 study is expected in the first half of 2027.”
Company press release, Aug 11, 2026 · SEC filing
first half of 2027 · “Study results will inform dose selection for potential future Phase 3 trials of TH103, and Kalaris remains on track to share initial data from the Phase 1b/2 study in the first half of 2027.”
Company press release, Jul 17, 2026 · SEC filing
second half of 2026 · “Kalaris expects to share preliminary data from the ongoing Phase 1b/2 study in the second half of 2026.”
Company press release, Dec 17, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KLRS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KLRS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.